Astellas v. Lupin: Consent Judgment Upholds Mirabegron Patent Rights in Landmark Pharma Case
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Astellas Pharma, Inc. v. Lupin Limited |
| Case Number | 1:23-cv-00819 (D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | July 28, 2023 – Feb 19, 2026 2 years 6 months |
| Outcome | Plaintiff Win — Permanent Injunction |
| Patents at Issue | |
| Accused Products | Lupin’s Mirabegron extended-release tablets (25 mg and 50 mg) |
Case Overview
The Parties
⚖️ Plaintiff
Global biopharmaceutical company and originator of Myrbetriq® (mirabegron), a blockbuster treatment for overactive bladder approved by the FDA. Astellas holds an extensive patent portfolio protecting the drug’s active compound, extended-release formulation, and manufacturing processes.
🛡️ Defendant
Major Indian generic pharmaceutical manufacturer with significant U.S. market operations. Lupin filed an Abbreviated New Drug Application (ANDA No. 209488) seeking to market generic Mirabegron extended-release tablets in 25 mg and 50 mg dosages — directly challenging Astellas’s market exclusivity.
The Patents at Issue
This landmark case involved four U.S. patents forming the core of this dispute. The infringement action arose under the Hatch-Waxman Act framework, triggered by Lupin’s ANDA filing with a Paragraph IV certification.
- • US11707451B2 — Mirabegron extended-release formulation (application US17/114890)
- • US ‘780 Patent — Related ER formulation technology
- • US ‘409 Patent — Related ER formulation technology
- • US ‘189 Patent — Related ER formulation technology
Developing a similar pharmaceutical formulation?
Check if your generic drug might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The court entered a consent judgment and final order on February 19, 2026. Based on Lupin’s admissions, all four asserted patents (‘780, ‘451, ‘409, and ‘189) were found **valid and enforceable**, and at least one claim of each patent was found **infringed** by the Lupin ANDA products. Lupin (including successors and assigns) is **permanently enjoined** from making, using, selling, offering to sell, importing, or distributing the ANDA products in the United States through the expiration of all four patents, including any patent term extensions, adjustments, pediatric exclusivity periods, or other regulatory exclusivities.
No specific monetary damages were awarded. The complaints across all four coordinated actions were dismissed **without prejudice and without costs** to either party.
Litigation Timeline & Procedural History
- July 28, 2023: Complaint filed in the U.S. District Court for the District of Delaware (Case No. 1:23-cv-00819).
- This action was part of a broader, coordinated litigation campaign by Astellas involving related civil actions — including Case Nos. 20-1589, 24-940, and 24-1069 — all before the same court.
- February 19, 2026: Consent judgment entered, closing the case after approximately 937 days of litigation. This duration is consistent with typical Hatch-Waxman district court timelines.
Legal Significance
This case reinforces a critical pattern in Hatch-Waxman litigation: **multi-patent assertion strategies materially increase settlement pressure on ANDA filers.** When a branded company constructs a patent estate with overlapping formulation, composition, and method claims — as Astellas has done with Mirabegron — generic challengers face the compounded risk of losing on any single patent, triggering injunctive relief regardless of success on others.
The consent judgment’s explicit extension of the injunction through **all regulatory exclusivities** — including pediatric exclusivity — is a drafting detail attorneys should note. This comprehensive scope prevents any exclusivity-gap strategy by the generic filer.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical extended-release formulations. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all 4 patents in this technology space
- See which companies are most active in OAB drug patents
- Understand claim scope of ER patents
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own generic formulation or compound.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Mirabegron extended-release formulations
4 Patents
In this formulation family
Design-Around Options
Available for some claims
✅ Key Takeaways
Multi-patent Hatch-Waxman assertion strategies create compounding settlement pressure on ANDA challengers.
Search related case law →Consent judgments should expressly extend injunctions through all patent term extensions, adjustments, and regulatory exclusivities.
Explore precedents →Frequently Asked Questions
The case involved four patents — referred to as the ‘780, ‘451, ‘409, and ‘189 patents — including U.S. Patent No. US11707451B2, covering Mirabegron extended-release tablet formulations in 25 mg and 50 mg dosages.
Lupin admitted that all four asserted patents are valid and enforceable and that at least one claim of each patent is infringed by its ANDA products, resulting in a permanent injunction through patent expiration.
The consolidated consent judgments across multiple Lupin-related actions effectively delay generic Mirabegron entry until expiration of the full patent family, including all patent term extensions and regulatory exclusivities.
Ready to Strengthen Your Pharmaceutical IP Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- United States District Court for the District of Delaware — Civil Action No. 1:23-cv-00819 (PACER)
- U.S. Patent and Trademark Office — U.S. Patent No. US11707451B2
- Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act)
- FDA — ANDA Resources
- PatSnap — Pharmaceutical IP Solutions
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.